OnabotulinumtoxinA for Trigeminal Neuralgia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

OnabotulinumtoxinA for Trigeminal Neuralgia — Stella

Home/Trigeminal Neuralgia/

View on ClinicalTrials.gov

Recruiting

Back to Trigeminal Neuralgia trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Meredith Barad, Stanford, California

Key details

Phase

Post-approval study

Sponsor

Stanford University

Enrollment target

~20 participants

Started

June 2024

Primary completion

February 2027

Age range

18 Years and older

Last updated January 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.